However, in the future, by exploring the impact of CD47 degradation in lysosomes on other signaling pathways and biological functions, the development of interventions targeting the CD47 lysosomal degradation process holds significant promise for enhancing the efficacy of cancer immunotherapy (Figure 1). Here, CD47 is linked to cancer.